PsychoGenics secures license for ENT1 inhibitor RO7117997 from Roche

PsychoGenics secures license for ENT1 inhibitor RO7117997 from Roche

PGI Drug Discovery LLC (PsychoGenics), recognized for its phenotypic drug discovery platform, has announced an exclusive license agreement with Roche. This agreement grants PsychoGenics global rights to develop, manufacture, and commercialize RO7117997, an Equilibrative Nucleoside Transporter 1 (ENT1) inhibitor, which is IND-ready. A Promising Candidate for Neuropsychiatric Disorders Discovered through a partnership utilizing PsychoGenics’ AI-enabled […]

Roche’s Vabysmo gains FDA approval for treating retinal vein occlusion

Roche’s Vabysmo gains FDA approval for treating retinal vein occlusion

Pharma giant Roche has secured the U.S. FDA’s approval for Vabysmo (faricimab) in treating macular edema after retinal vein occlusion (RVO). This becomes the third indication for Vabysmo, joining the ranks alongside neovascular or ‘wet’ age-related macular degeneration (nAMD) and diabetic macular edema (DME). Collectively, these three retinal ailments affect an estimated 70 million individuals […]

Roche announces $7.1bn deal to acquire Telavant and RVT-3101 antibody

Roche announces $7.1bn deal to acquire Telavant and RVT-3101 antibody

Switzerland-based Roche has officially declared its acquisition agreement for Telavant Holdings, Inc., a Roivant company collaboratively owned by Roivant Sciences Ltd. and Pfizer Inc. The spotlight of this $7.1 billion deal is on RVT-3101, a novel TL1A directed antibody, poised as a potential game-changer for nearly 8 million global inflammatory bowel disease patients, including those […]

Roche, Alnylam’s Zilebesiran meets primary endpoint in KARDIA-1 trial

Roche, Alnylam’s Zilebesiran meets primary endpoint in KARDIA-1 trial

Breaking news in the world of hypertension treatment, Roche and Alnylam Pharmaceuticals have announced the success of their Phase 2 study KARDIA-1. The investigational RNAi therapeutic Zilebesiran met its primary and secondary endpoints in treating adult patients with hypertension. Primary and Secondary Endpoints Achieved Zilebesiran succeeded in significantly reducing systolic blood pressure (SBP) by over […]

Genentech’s Alecensa shows promise in Phase III ALINA study for early-stage ALK-positive NSCLC

Genentech’s Alecensa shows promise in Phase III ALINA study for early-stage ALK-positive NSCLC

Genentech, a Roche Group member, has announced positive results from its Phase III ALINA study evaluating Alecensa (alectinib), setting a new standard for treating early-stage anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC). Meeting its primary endpoint of disease-free survival (DFS), Alecensa showed a statistically significant and clinically meaningful improvement compared to platinum-based chemotherapy. […]

Genentech bags Lunsumio FDA approval for R/R follicular lymphoma

Genentech bags Lunsumio FDA approval for R/R follicular lymphoma

Lunsumio FDA approval : Genentech, a subsidiary of the Roche Group, has secured the approval of the US Food and Drug Administration (FDA) for Lunsumio (mosunetuzumab-axgb) for the treatment of relapsed or refractory (R/R) follicular lymphoma (FL) in adults, subjected to two or more treatments for their cancer. Lunsumio is a CD20xCD3 T-cell engaging bispecific […]

Genentech gets Actemra FDA approval for COVID-19 in hospitalized adults

Genentech gets Actemra FDA approval for COVID-19 in hospitalized adults

Actemra FDA approval : Genentech, a subsidiary of Roche, has received the approval of the US Food and Drug Administration (FDA) for Actemra (tocilizumab) intravenous (IV) for the treatment of COVID-19. Actemra intravenous is indicated for the treatment of adult patients who are hospitalized and receiving systemic corticosteroids and supplemental oxygen. Recommended for use as […]